HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell

The company dosed its first patient in the Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy for relapsed/refractory kappa-restricted multiple myeloma. The initial patient was monitored after dosing, and the treatment was reported as well tolerated with no early safety concerns highlighted. This early-stage clinical progress is a positive near-term catalyst, though it is unlikely to materially move markets beyond the specific biotech name.